Market Research Logo

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Plaque Psoriasis (Psoriasis Vulgaris) Overview
Therapeutics Development
Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies
Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development
3SBio Inc.
Amgen Inc.
AstraZeneca Plc
Avesthagen Limited
Avexxin AS
BIOCAD
Biocon Limited
Bionovis SA
Can-Fite BioPharma Ltd.
Celgene Corporation
Celltrion, Inc.
Creabilis SA
Delenex Therapeutics AG
Dermira Inc.
Epirus Biopharmaceuticals, Inc.
Forward Pharma A/S
Galectin Therapeutics, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
Hetero Drugs Limited
Idera Pharmaceuticals, Inc.
Invion Limited
Johnson & Johnson
Kadmon Corporation, LLC
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
LEO Pharma A/S
Lipidor AB
Mabion SA
Mabtech Limited
Maruho Co., Ltd.
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Oncobiologics, Inc.
Pfizer Inc.
Promius Pharma, LLC
Protalix BioTherapeutics, Inc.
Provectus Biopharmaceuticals, Inc.
R-Tech Ueno, Ltd.
TetraLogic Pharmaceuticals
Therapeutic Proteins International, LLC
UCB S.A.
Valeant Pharmaceuticals International, Inc.
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(betamethasone dipropionate + calcipotriene) - Drug Profile
(calcipotriene + betamethasone dipropionate) - Drug Profile
(calcipotriene + betamethasone) - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
AM-001 - Drug Profile
AVX-001 - Drug Profile
betamethasone valerate + maxacalcitol - Drug Profile
bimekizumab - Drug Profile
bleselumab - Drug Profile
brodalumab - Drug Profile
calcipotriene - Drug Profile
CC-90005 - Drug Profile
CT-327 - Drug Profile
dalazatide - Drug Profile
DFD-01 - Drug Profile
DFD-06 - Drug Profile
dimethyl fumarate - Drug Profile
DLX-105 - Drug Profile
DNX-114 - Drug Profile
DNX-514 - Drug Profile
DRM-02 - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
GK-664S - Drug Profile
GRMD-02 - Drug Profile
GSK-2981278 - Drug Profile
guselkumab - Drug Profile
IDP-118 - Drug Profile
IDP-122 - Drug Profile
IMO-8400 - Drug Profile
IMP-731 - Drug Profile
infliximab biobetter - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
INV-103 - Drug Profile
KD-025 - Drug Profile
LEO-32731 - Drug Profile
LP-0113 - Drug Profile
M-7040 - Drug Profile
MOL-4239 - Drug Profile
MOL-4249 - Drug Profile
pefcalcitol - Drug Profile
PF-04965842 - Drug Profile
PF-06700841 - Drug Profile
PH-10 - Drug Profile
piclidenoson - Drug Profile
RTU-1096 - Drug Profile
SHP-141 - Drug Profile
tofacitinib - Drug Profile
toreforant tartrate - Drug Profile
UCB-5857 - Drug Profile
ustekinumab biosimilar - Drug Profile
Plaque Psoriasis (Psoriasis Vulgaris) - Recent Pipeline Updates
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products
Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by 3SBio Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avesthagen Limited, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celgene Corporation, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Creabilis SA, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Dermira Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Galectin Therapeutics, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Hetero Drugs Limited, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Invion Limited, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kineta, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mabion SA, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mabtech Limited, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by R-Tech Ueno, Ltd., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TetraLogic Pharmaceuticals, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H2 2015
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report